Sabby Management’s Galectin Therapeutics GALT Stock Holding History

Sabby Management’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-210	Closed	-$100K	–	157
2018 Q1	$100K	Sell	210 -921	-81%	-$4.29K	0.01%	134
2017 Q4	$378K	Buy	1,131 +794	+236%	+$2.01K	0.03%	109
2017 Q3	$72K	Sell	337 -304	-47%	-$602	﹤0.01%	149
2017 Q2	$158K	Sell	641 -199	-24%	-$530	0.01%	184
2017 Q1	$193K	Buy	840 +605	+257%	+$912	0.01%	217
2016 Q4	$23K	Sell	235 -590	-72%	-$524	﹤0.01%	290
2016 Q3	$93K	Buy	+825	New	+$1.47K	﹤0.01%	292

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FFA

First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Sabby Management's GALT Position: Q3 2018 in Review

Sabby Management sold out of Galectin Therapeutics (GALT) in Q3 2018, closing a stake of 14,029 shares — an estimated $89K sold.

Sabby Management first reported a position in GALT in Q4 2014 and held it in 7 quarters. The position peaked at $1.78M in Q4 2015. 60 funds tracked by Wall St. Rank hold GALT as of Q3 2018.

Sabby Management reported no remaining Galectin Therapeutics position as of Q3 2018 after selling out during the quarter.
Sabby Management sold 14,029 Galectin Therapeutics shares in Q3 2018, an estimated $89K.
Sabby Management first reported a position in Galectin Therapeutics in Q4 2014 and held it in 7 quarters.
Sabby Management's Galectin Therapeutics position peaked at $1.78M in Q4 2015.
60 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2018.

Based on Sabby Management's 13F filing for Q3 2018, filed 14 Nov 2018.